Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
Executive Summary
Fallout from the withdrawal of Vioxx (rofecoxib) will likely have an impact on post-marketing surveillance methods for COX-2 inhibitors and other drugs
You may also be interested in...
Interview: CrystalGenomics, First Korean Bioventure To ‘Go All The Way’
After reaching milestones by launching a novel osteoarthritis drug and licensing out an AML candidate to a US partner, CrystalGenomics’ CEO talks to Scrip about what else is in store for the South Korean bioventure in 2017 and beyond.
Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits?
Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.
NSAID Panel Highlights Challenge Of Getting Comparative Safety Claim
Does wide public health concern warrant flexibility in regulatory standards for safety claims? An advisory panel on cardiovascular risk of NSAIDs spotlights the dual challenge of accurately determining drug risks and communicating risks in informative way.